Nicola J Curtin (Nicola Curtin)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 21

Top Topics

Induced Apoptosis

Dna Damage Response

Top Venues

Biochemical Society transactions

Expert reviews in molecular medicine

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Hannah L Smith, Elaine Willmore, Lisa Prendergast, Nicola J Curtin
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. British journal of cancer 131 (5) (2024)
Hannah L Smith, Elaine Willmore, Lisa Prendergast, Nicola J Curtin
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. British journal of cancer (2024)
Nicola J Curtin
Targeting the DNA damage response for cancer therapy. Biochemical Society transactions 51 (1) (2023)
Nicola J Curtin
Targeting the DNA damage response for cancer therapy. Biochemical Society transactions (2023)
Nicola J Curtin
Targeting the DNA damage response for cancer therapy. Biochemical Society transactions 51 (1) (2023)
Nicola J Curtin
Targeting the DNA damage response for cancer therapy. Biochemical Society transactions 51 (1) (2023)
Nicola J Curtin
Targeting the DNA damage response for cancer therapy. Biochemical Society transactions 51 (1) (2023)
Nicola J Curtin
25 years of ERMM . Expert reviews in molecular medicine 25 (2023)
Alice Bradbury, Frank T Zenke, Nicola J Curtin, Yvette Drew
The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response. Cells 11 (15) (2022)
Hannah L Smith, Elaine Willmore, Asima Mukhopadhyay, Yvette Drew, Nicola J Curtin
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling. Cancers 14 (22) (2022)
Santu Saha, Stuart Rundle, Ioannis C Kotsopoulos, Jacob Begbie, Rachel Howarth, Isabel Y Pappworth, Asima Mukhopadhyay, Ali Kucukmetin, Kevin J Marchbank, Nicola J Curtin
Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy. Cancers 14 (17) (2022)
David King, Harriet E D Southgate, Saskia Roetschke, Polly Gravells, Leona Fields, Jessica B Watson, Lindi Chen, Devon Chapman, Daniel Harrison, Daniel Yeomanson, Nicola J Curtin, Deborah A Tweddle, Helen E Bryant
Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers 13 (24) (2021)
Sweta Sharma Saha, Lucy Gentles, Alice Bradbury, Dominik Brecht, Rebecca Robinson, Rachel O'Donnell, Nicola J Curtin, Yvette Drew
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. Cancers 13 (6) (2021)
Alice Bradbury, Rachel O'Donnell, Yvette Drew, Nicola J Curtin, Sweta Sharma Saha
Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting. Cancers 12 (7) (2020)
Nicola J Curtin, Péter Bai
PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer. Cancers 12 (12) (2020)
Harriet E D Southgate, Lindi Chen, Deborah A Tweddle, Nicola J Curtin
ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms. Cancers 12 (5) (2020)
Nicola J Curtin, Yvette Drew, Sweta Sharma-Saha
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nature reviews. Clinical oncology 16 (12) (2020)
Hannah L Smith, Harriet Southgate, Deborah A Tweddle, Nicola J Curtin
DNA damage checkpoint kinases in cancer. Expert reviews in molecular medicine 22 (2020)
Hannah L Smith, Lisa Prendergast, Nicola J Curtin
Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells. Cancers 12 (4) (2020)
Judith E Unterlass, Nicola J Curtin
Warburg and Krebs and related effects in cancer. Expert reviews in molecular medicine 21 (2019)
Miriam Franklin, Lucy Gentles, Elizabeth Matheson, Nick Bown, Paul Cross, Angela Ralte, Connor Gilkes-Immeson, Alice Bradbury, Maryam Zanjirband, John Lunec, Yvette Drew, Rachel O'Donnell, Nicola J Curtin
Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor. Cancer medicine 7 (9) (2018)